True North Advisors LLC Acquires 55 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

True North Advisors LLC grew its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 9.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 624 shares of the medical research company’s stock after buying an additional 55 shares during the quarter. True North Advisors LLC’s holdings in Thermo Fisher Scientific were worth $325,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Traynor Capital Management Inc. bought a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at approximately $211,000. Wesbanco Bank Inc. lifted its holdings in shares of Thermo Fisher Scientific by 12.3% in the 4th quarter. Wesbanco Bank Inc. now owns 42,973 shares of the medical research company’s stock worth $22,356,000 after acquiring an additional 4,696 shares during the last quarter. R.H. Dinel Investment Counsel Inc. grew its holdings in Thermo Fisher Scientific by 4.9% during the 4th quarter. R.H. Dinel Investment Counsel Inc. now owns 20,331 shares of the medical research company’s stock valued at $10,577,000 after purchasing an additional 950 shares during the last quarter. Magnus Financial Group LLC lifted its stake in Thermo Fisher Scientific by 67.9% in the fourth quarter. Magnus Financial Group LLC now owns 5,703 shares of the medical research company’s stock worth $2,967,000 after purchasing an additional 2,306 shares during the last quarter. Finally, Advisory Alpha LLC grew its stake in shares of Thermo Fisher Scientific by 12.5% during the fourth quarter. Advisory Alpha LLC now owns 1,432 shares of the medical research company’s stock valued at $745,000 after buying an additional 159 shares during the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

TMO has been the topic of several research analyst reports. Stephens assumed coverage on Thermo Fisher Scientific in a research report on Tuesday, October 1st. They issued an “overweight” rating and a $680.00 price objective on the stock. Stifel Nicolaus reduced their price target on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a research note on Thursday, October 24th. Barclays lowered their price objective on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating for the company in a research report on Wednesday, October 23rd. Wells Fargo & Company decreased their price target on shares of Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating for the company in a research note on Thursday, October 24th. Finally, Royal Bank of Canada reduced their price objective on Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. Four analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $648.95.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Monday, October 28th. The shares were sold at an average price of $554.29, for a total value of $5,542,900.00. Following the sale, the chief executive officer now owns 121,192 shares in the company, valued at $67,175,513.68. This represents a 7.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of the business’s stock in a transaction on Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the transaction, the senior vice president now owns 12,736 shares of the company’s stock, valued at $7,134,197.76. This represents a 13.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 47,150 shares of company stock worth $25,954,465. 0.34% of the stock is currently owned by insiders.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $574.72 on Thursday. Thermo Fisher Scientific Inc. has a 12 month low of $493.30 and a 12 month high of $627.88. The stock has a fifty day moving average price of $530.86 and a 200-day moving average price of $568.96. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. The firm has a market cap of $219.83 billion, a PE ratio of 36.03, a P/E/G ratio of 3.81 and a beta of 0.76.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, beating the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The firm had revenue of $10.60 billion during the quarter, compared to analyst estimates of $10.63 billion. During the same period last year, the firm posted $5.69 EPS. Thermo Fisher Scientific’s revenue was up .2% on a year-over-year basis. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 21.68 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, January 15th. Investors of record on Friday, December 13th were paid a $0.39 dividend. The ex-dividend date was Friday, December 13th. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.78%.

Thermo Fisher Scientific announced that its Board of Directors has approved a share repurchase program on Friday, November 15th that authorizes the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to buy up to 2% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s leadership believes its shares are undervalued.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.